136 results
8-K
EX-99.1
ABBV
Abbvie Inc
26 Apr 24
AbbVie Reports First-Quarter 2024 Financial Results
7:43am
of the organization we have built over the past 11 years. We’ve established an exemplary company culture, developed a productive R&D engine, delivered top-tier … , research and development (R&D) expense was 15.8 percent of net revenues. The adjusted R&D expense was 14.7 percent of net revenues.
Acquired IPR&D
8-K
EX-99.1
nzybkw7pnhmo3yrnlfr
20 Feb 24
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
9:00am
8-K
EX-99.1
q84qn8dfvofh1
12 Feb 24
AbbVie Completes Acquisition of ImmunoGen
7:49am
8-K
EX-99.1
ahlb3zjs
2 Feb 24
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
7:51am
8-K
EX-99.2
hgg4xl9
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.2
azese
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.1
ud8v 49ltzz
27 Oct 23
AbbVie Reports Third-Quarter 2023 Financial Results
7:49am
8-K
EX-99.1
upwrli
27 Jul 23
AbbVie Reports Second-Quarter 2023 Financial Results
7:45am
8-K
EX-99.1
7c5gsl aem13
27 Apr 23
AbbVie Reports First-Quarter 2023 Financial Results
7:36am
8-K
EX-99.1
s9rt6r75myvl
28 Oct 22
AbbVie Reports Third-Quarter 2022 Financial Results
7:48am